You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company has developed a technology for isolating cancer DNA in urine along with specialized PCR assays to identify biomarkers that it believes will offer more accurate and sensitive detection of hepatocellular carcinoma.
The firm expects to begin distributing shipments of its FTL3 assay from LabPMM GK, the marketing authorization holder in Japan, in late 2018.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
The company is also beginning work on other products in its pipeline, including a test specifically aimed at questions around the management of sepsis.
Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
Atomo's tests use the firm's AtomoRapid technology to detect the presence of HIV antibodies from a finger prick of blood and provides results within 15 minutes.
Canon Medical Systems established the Japanese joint venture — called ACTmed — with Taiwanese molecular diagnostics firm ACT Genomics.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The financing will go toward driving adoption of the company's technology, which can distinguish bacterial infections from viral ones, and other purposes.